Direxion Daily Pharmaceutical & Medical Bull 3X ETF

PILL

Market cap $14.2M

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

On Thursday, news broke that the US will likely start levying a 100% tariff on branded pharmaceutical imports. The specifics remain unclear, but the levy is expected to be relatively narrow in scope, since many exemptions have already been negotiated.

Europe's pharmaceutical industry needs to make sure it doesn't become yesterday's news. Its biopharmaceutical innovation capacity has been gradually declining for decades, and the rapid ascent of China and President Trump's policies risk accelerating that decay.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

After a relatively sluggish 2024 for mergers & acquisitions (M&A) activity in the biopharma sector, the environment could be more conducive for deals in the rest of 2025. The industry, like the rest of the capital markets, will be keeping an eye on interest rates as monetary easing by the U.S.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.